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Abstract
Background An association between CYP2D6 polymorphisms and tamoxifen (TAM) efficacy has not been confirmed, partly 
due to unreliable prediction of active metabolite exposure solely by CYP2D6 activity. The efficacy of TAM dose escala-
tion appears limited in poor TAM metabolizers. Since the chlorine atom on the side chain of toremifene (TOR) prevents 
4-hydroxylation by CYP2D6, its contribution to active conversion of TOR is minor. We examined the role of TOR and its 
dose escalation among poor TAM metabolizers.
Methods The pharmacokinetics (PK) and pharmacogenomics (PGx) of TAM and TOR were studied. Correlation between 
PK and CYP2D6 inhibitor use, smoking status, and PGx were examined by regression analysis. For patients showing low 
endoxifen levels, an intra-patient dose escalation of TOR was conducted, and TOR was increased from 40 to 120 mg for ≥ 24 
weeks with PK sampling. Total activity was calculated as the sum of the concentration of each active metabolite adjusted 
by their respective in vitro activities.
Results Fifty and 11 of the 273 participating patients had endoxifen levels < 15 and < 7.5 ng/mL, respectively. The CYP2D6 
genotype was the major determinant for TAM activity (p < 0.01). Smoking status (p = 0.07) and the CYP2C19 phenotype 
(p = 0.07), but not the CYP2D6 genotype (p = 0.61), showed marginally significant effects on TOR activity. TOR activity 
increased significantly with dose escalation, even among poor TAM metabolizers, and was maintained for ≥ 24 weeks.
Conclusion TOR might be a valid alternative to TAM in patients predicted to be poor TAM metabolizers.
Keywords Tamoxifen · Toremifene · CYP2D6 · Pharmacokinetics · Breast cancer
Introduction
The relationship between CYP2D6 polymorphisms and the 
therapeutic effects of tamoxifen (TAM) has been studied for 
a decade, but the results are contradictory and inconclusive. 
Regarding the question raised in the article [1], “How pre-
dictive is the CYP2D6 genotype for endoxifen and 4-hydroxy 
(4OH)-TAM levels?” the data show that this genotype can be 
used to compare populations, but there are large overlaps in 
pharmacokinetics/pharmacodynamics (PK/PD) of individual 
patients belonging to different genotype groups. There are 
several possible explanations for the variations in the lit-
erature [1–3]. First, the frequencies of the CYP2D6 alleles 
differ between Asian and Caucasian populations, resulting 
in inconsistencies in the effects of TAM depending on the 
study location. Second, the methodology, classification, 
and scoring used for CYP2D6 polymorphisms differ among 
studies. Third, because many other enzymes are involved 
in the metabolism, it is impossible to explain the differ-
ences in the PK/PD solely using CYP2D6 polymorphisms. 
Association between tamoxifen PK and CYP2C19 [4] or 
ABCC2 (rs3740065) [5] polymorphism has been reported. 
Fourth, concomitant usage of CYP2D6 inhibitors has a 
greater impact on PK than genetic polymorphisms. Fifth, 
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poor compliance among extensive metabolizers (EMs) is 
expected. Sixth, retrospective studies with samples chosen 
based on availability and representing a small proportion of 
the overall population are not representative of the entire 
population and are statistically underpowered. Finally, geno-
typing from formalin-fixed, paraffin-embedded specimens 
may not be as accurate as that from the DNA of blood lym-
phocytes, because somatic deletion at the CYP2D6 chromo-
somal locus is relatively common in breast cancer. Unless 
these issues are addressed, conducting similar studies will 
not determine the influence of CYP2D6 polymorphisms on 
the therapeutic effects of TAM.
Even among genetically determined EMs, large inter-
patient variability exists in the plasma concentrations of 
active metabolites, endoxifen, and 4OH-TAM. A significant 
proportion of EMs have blood levels of active metabolites 
close to those of patients who are genotypically homozygous 
for unstable enzymes with reduced activity alleles [6, 7], 
and some even have levels close to those of patients who 
are genotypically homozygous for nonfunctional alleles [8]. 
In addition, patients who concurrently take selective sero-
tonin reuptake inhibitors such as paroxetine achieve similar 
active metabolite concentrations to those who are genotypi-
cally homozygous for nonfunctional alleles [8]. Although 
Wu et al. indicated that endoxifen levels in the blood can be 
estimated from information such as age, race, and genotype 
[9], direct determination of drug concentrations is consid-
ered a more suitable approach, as is common practice for 
anticonvulsants and immunosuppressants.
Recent clinical pharmacology studies have indicated 
that simply increasing the dose of TAM may not overcome 
the genetically reduced enzymatic activity of CYP2D6 [6, 
10]. Therefore, we chose a different strategy using another 
selective estrogen-receptor modulator that is metabolically 
independent of CYP2D6, toremifene (TOR), and conducted 
a clinical pharmacology study to confirm the effectiveness 
of our strategy. We enrolled breast cancer patients with low 
endoxifen levels on 20 mg of TAM into our intra-patient 
dose-escalation study of TOR (initial dose, 40 mg; escalated 
dose, 120 mg), for which the contribution of CYP2D6 to 
its bioactivation seemed lower than that for TAM [11], to 
investigate the intra-patient differences in the total activity 
of TOR calculated by the blood concentrations of the active 
metabolites between the 40- and 120-mg doses.
Patients and methods
Study design and patient population
The present study includes the screening study “Pharma-
cokinetics–pharmacogenomics study in breast cancer endo-
crine treatment” and an intra-patient dose-escalation clinical 
pharmacology study for TOR, “PGx–PK-based clinical 
pharmacology study of anti-estrogens.”
For the screening study, we enrolled any breast cancer 
patients taking either TAM or TOR who maintained good 
(85% or above) compliance for at least 12 weeks, with ade-
quate organ function. Patients who needed regular use of 
CYP2D6 inhibitors such as paroxetine, sertraline, amiodar-
one, or metoclopramide were excluded.
The eligibility criteria for the intra-patient dose-escala-
tion clinical pharmacology study for TOR included breast 
cancer patients who had participated in the screening study 
and were found to have very low-active metabolite levels as 
defined by endoxifen levels of < 7 (about a half of endoxifen 
concentration for extensive metabolizers) or low endoxifen 
levels of < 15 ng/ml (about a quarter of endoxifen concentra-
tion for extensive metabolizers) with one of the following 
three features such as no hot flushes, at least one null geno-
type for CYP2D6 (*3, 4, 5, 14, 18, 21, 44), or two alleles 
of a low-activity genotype for CYP2D6 (*9 or 10). Patients 
taking CYP2D6 inhibitors or who had a history of thrombo-
embolism, severe comorbidities, or inadequate organ func-
tion were excluded. Written informed consent was obtained 
from all the participants included in the study. The patient 
enrolment period for the screening study started on February 
1, 2009 and ended on July 31, 2012. The enrolment period 
for the intra-patient dose-escalation clinical pharmacology 
study for TOR started on November 1, 2009 and ended on 
November 30, 2013.
Pharmacogenomics
Pharmacogenomics (PGx) analysis for CYP2D6, CYP2C19, 
and ABCC2 (MRP2) was conducted by FALCO Biosystems 
(Kyoto, Japan). Genomic DNA was extracted from the whole 
blood of patients using a QIAamp DNA Blood Mini Kit 
(QIAGEN GmbH, Hilden, Germany). CYP2D6*3, *4, *9, 
and *10 were genotyped by an allele-specific PCR assay fol-
lowed by agarose gel electrophoresis. CYP2D6*5 was geno-
typed by a long-range PCR assay followed by agarose gel 
electrophoresis as described previously [9, 10]. CYP2D6*14, 
*18, *21, and *44, and MRP2 (rs3740065) were genotyped 
by Sanger sequencing using the 3103xl Genetic Analyzer, 
and Sequencing Analysis Software (v5.3.1; Life Technolo-
gies Corporation, Carlsbad, CA, USA) was used for the anal-
ysis. CYP2C19*2 and *3 were genotyped by the TaqMan 
Drug Metabolism Assay (Life Technologies Corporation) 
for *2 (C__25986767_70) and *3 (C__27861809_10) using 
the 7900HT Sequence Detection System, with analysis by 
the SDS Software (v2.3; Life Technologies Corporation).
These genotypes are classified into six subtypes, as fol-
lows: type 1, homozygous for two null genotypes (*3, *4, *5, 
*14, *18, *21, *44); type 2, null/wild; type 3, homozygous 
for two low-active genotypes (*9 or *10), low/low; type 4, 
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null/low; type 5, low/wild; type 6, wild/wild. The CYP2C19 
genotypes are classified into: EM, homozygous for wild type; 
poor metabolizer (PM), homozygous for mutant allele (*2, 
*3); intermediate metabolizer (IM), heterozygous (*2/wild 
or *3/wild).
Pharmacokinetics
Blood samples for PK analysis were obtained from patients 
who had good compliance with taking medications 2–4 h 
after taking anti-estrogens. For the intra-patient dose-esca-
lation clinical pharmacology study for TOR, blood sampling 
was performed after administering TOR 40 mg for at least 
4 weeks, after which the dose was increased to 120 mg. PK 
sampling was performed twice: the first sampling was per-
formed after at least 4 weeks when PK reached a steady 
state; 120 mg TOR was administered for another 20–28 
weeks after which the second sampling was performed 
to assess PK stability over time (Figure S1). The plasma 
was analyzed for the concentrations of TAM and TOR, as 
well as the 4OH-, N-desmethyl (NDM-), and 4-hydroxy-
N-desmethyl (4OH-NDM-) metabolites of TAM and TOR, 
respectively, using LC–MS/MS by NAC Co., Ltd., under the 
“Guidance for Industry: Bioanalytical Method Validation” 
issued in May 2001 by the US Department of Health and 
Human Services, the Food and Drug Administration, the 
Center for Drug Evaluation and Research, and the Center for 
Veterinary Medicine. Standard curves were prepared in the 
concentration range of 20–2000 ng/mL for TOR, 4OH-TOR, 
TAM, and 4OH-TAM, and 0.20–50 ng/mL for NDM-TOR, 
4OH-NDM-TOR, and NDM-TAM, and 0.50–50 ng/mL for 
endoxifen. The interday variability and intraday variability 
for all compounds are within 15%.
The total activity of TAM was calculated as 
1 . 0  ×  TA M  +  0 . 6 5 5  ×  N D M -TA M  +  1 1 6  ×  4 O H -
TAM + 46.3 × endoxifen, and the total activity of TOR was 
calculated as 1.0 × TOR + 0.764 × NDM-TOR + 98.0 × 4OH-
TOR + 91.9 × 4OH-NDM-TOR [11].
Adverse events and intra‑patient dose escalation
We obtained data on compliance and the grade of hot flush 
as defined by the Common Terminology Criteria for Adverse 
Events v3.0.
Patients were started on 40 mg of TOR. After 4 weeks, 
the dose of TOR was increased to 120 mg, and continued as 
long as adverse events for which a causal relationship with 
TOR could not be ruled out did not exceed grade 1.
Data management and statistical methodology
Because no previous clinical trials have used the total 
activity as an endpoint, the patient sample size for the 
intra-patient dose-escalation clinical pharmacology study 
for TOR was tentatively calculated as 30 to show that the 
total activity of TOR 120 mg is statistically higher than that 
of TOR 40 mg with a 95% confidence interval, assuming that 
20% of the patients will not complete the entire study period. 
Sample sizes for the screening study were set at 200 and 100 
for TAM- and TOR-treated patients, respectively, to attain 
approximately 60 poor metabolizers (PMs) for TAM, with 
twice as many candidates for the intra-patient dose-escala-
tion clinical pharmacology study for TOR. A paired t test 
or McNemar’s test was used to compare the adverse events 
between different TOR doses/timing. The p value was not 
calculated if there were no events. Paired or unpaired t tests 
were used to compare the TOR metabolite concentration or 
the total activity between different doses/timing of TOR.
Results
Patients’ background
Figure 1 illustrates the study schema. The full analysis set 
for the screening study included 273 patients. Among them, 
182 patients were on TAM, and 61 and 30 patients were on 
TOR 40 mg and 120 mg, respectively. PK sampling was 
not conducted for three patients on TOR 120 mg. Table 1 
shows the background of these patients. A lower grade and 
frequency of hot flushes was observed in patients taking 
TOR 120 mg than in the patients taking TAM 20 mg or 
TOR 40 mg. Low percentages of the patients were current 
smokers (5.5%) or users of CYP inhibitors (10.6%). Only 
one patient used strong CYP2D6 inhibitor (paroxetine). 
Figure 2a, b illustrates the relationship between CYP2D6 
phenotype and endoxifen concentration or the total activ-
ity of TAM. Comparably, low concentrations of endoxifen 
and total activity were found in the patients with CYP2D6 
low/low and CYP2D6 null/low genotype. In addition, sig-
nificant proportions of patients with low/wild and wild/wild 
genotypes had low concentrations of endoxifen and total 
activity, which are similar results to those for the patients 
with CYP2D6 low/low and CYP2D6 null/low genotypes.
Among the 182 patients on TAM, 50 patients had 
endoxifen levels lower than 15  ng/mL. Among these 
patients, 14 PMs of TAM as defined by endoxifen con-
centration and CYP2D6 genotype were enrolled in the 
intra-patient dose-escalation clinical pharmacology study 
for TOR. Table 2 shows the background of these patients. 
Among the 14 patients enrolled, 12 patients completed 
the study, and PK data were obtained for these patients. 
No patients had the wild/wild genotype for CYP2D6, and 
50% of these patients were homozygous for the low pheno-
type. The mean and median concentrations for endoxifen 
in the patients on 20 mg of TAM were 9.7 and 10.4 ng/mL, 
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respectively, in contrast with 23.3 and 22.6 ng/mL for the 
entire population, respectively.
Pharmacokinetics
Table S1 shows a summary of the concentrations of TAM, 
TOR, and their metabolites. The mean and median endox-
ifen concentrations were 23.5 and 22.8 ng/mL, respec-
tively, with large intra-patient variability (1.8–64.5 ng/
mL) for patients taking TAM 20 mg a day. The mean 
and median concentrations of the other active metabo-
lite of TAM, 4OH-TAM, were only 3.6 and 3.3 ng/mL, 
respectively.
The mean concentrations of the 4OH metabolites of 
TOR, 4OH-TOR and 4OH-NDM-TOR, in the patients tak-
ing TOR 40 mg were 8.1 and 15.4 ng/mL, and in those tak-
ing TOR 120 mg were 16.0 and 32.6 ng/mL, respectively, 
compared to the concentrations of the parent compound, 
TOR, in those taking TOR 40 mg (732 ng/mL) and those 
taking TOR 120 mg (1957.5 ng/mL), indicating a lower 
contribution of the 4OH-metabolizing enzyme, CYP2D6, 
for TOR than for TAM.
Multiple regression analysis of TAM and TOR 
pharmacokinetics
As shown in Table 3, the CYP2D6 phenotype was signifi-
cantly associated with the total activity of TAM but not 
for TOR. On the other hand, in addition to the TOR dose, 
current smoking status and CYP2C19 phenotype seem to 
be associated with TOR activity.
Intra‑patient dose escalation and adverse events
With an increase in the dose of TOR, only a few patients 
developed hot flushes and GOT/GPT elevation (Table S2). 
Body weight remained stable.
Figure 3a, b shows the total activity of TOR in the screen-
ing study and during intra-patient dose escalation, respec-
tively. Almost all the metabolites increased in concentra-
tion at least twofold after increasing the dose from 40 to 
120 mg (data not shown). The total activity also increased 
by at least twofold (p < 0.01, Fig. 3a, b). By continuing the 
same dose of TOR for up to 6 months, the concentration of 
TOR and its metabolites, as well as the total activity of TOR, 
remained constant, although there was a trend for decreased 
total activity after 24 week continuation of high-dose TOR 
(Fig. 3a, b).
Discussion
This is one of the few studies in which data on both con-
comitant use of CYP inhibitors (both 2D6 and 3A4) and an 
extensive list of genetic polymorphisms within CYP2D6, 
CYP2C19, and ABCC2 were analyzed together, with data 
obtained from a non-Caucasian population. The results of 
the screening component of the study indicated that the 
CYP2D6 phenotype is the major determinant for TAM 
activity but not for TOR. Conversely, significant propor-
tions of patients with CYP2D6 low/wild and wild/wild gen-
otypes who were not using concurrent CYP2D6 inhibitors 
had lower endoxifen levels comparable to those of patients 
with the low/low and null/low genotypes, which may suggest 
the importance of therapeutic drug monitoring to optimize 
Fig. 1  Diagram showing clini-
cal trial enrollment and study 
schema
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drug exposure for individual patients. Furthermore, the 
intra-patient dose-escalation part of the study showed that 
switching to TOR 40 mg and increasing the dose to 120 mg 
is a valid option to overcome TAM underexposure for PMs 
of TAM.
There are several limitations in this study. First, the only 
endocrine-related adverse event evaluated was hot flushes, 
and other symptoms reportedly related to TAM efficacy 
such as night sweats, musculoskeletal adverse events, and 
vulvovaginal symptoms were not evaluated [12–14]. Fre-
quency and severity of adverse events were difficult to 
assess, because both pre- and post-menopausal patients, 
as well as patients using LH–RH analog participated in 
this study. Second, because we did not evaluate direct 
anti-tumor effects such as clinical response or recurrence, 
we cannot rule out the possibility that even patients with 
relatively low exposure to the active metabolites (such as 
endoxifen levels < 15 ng/ml) could have received similar 
clinical benefits with enough exposure. Similarly, exposure 
achieved with TOR 120 mg may provide no advantage over 
that with TOR 40 mg in terms of clinical efficacy, because 
there are limited data for a direct comparison of the two 
doses. Third, since we could not conduct comprehensive 
analysis of all possible variant genotypes, this might have 
classified a few patients into different category. Fourth, 
total activity calculated in this study was not widely used. 
Because analysis for TOR has not been well conducted 
in the past, it was difficult to select single metabolite for 
estimation of its activity, since all metabolites contribute 
to the activity. Fifth, PK sampling time in this study might 
not be optimal and can be a cause of variability. Finally, 
although we have excluded the patients who regularly use 
CYP2D6 inhibitor, such as paroxetine, use of all currently 
established strong or moderate CYP2D6 inhibitors was 
not excluded.
A Cochrane meta-analysis of seven randomized-con-
trolled trials indicated that TOR and TAM are equally effec-
tive in patients with advanced breast cancer, although some 
toxicities such as headache (risk ratio 0.14, p = 0.02), ocular 
disorders (risk ratio 0.46, p = 0.10), and endometrial cancer 
(risk ratio 0.22, p = 0.10) seem to be more common for TAM 
[15]. This analysis included mostly Western patient popula-
tions (n = 2061), except for one Japanese study with only 57 
patients in each arm. The prevalence of the CYP2D6 allele 
with reduced activity (CYP2D6*10) is significantly higher 
in Asian populations [16]. Therefore, we need to be care-
ful when adapting clinical trial data obtained from mostly 
Caucasian patients, because they have significantly different 
genetic backgrounds to Asian patients.
In a genotype-guided intra-patient dose-escalation study 
of TAM conducted in the US, the endoxifen concentra-
tions among patients homozygous for CYP2D6 PM (11/118 
patients) genotype (*3, *4, *5, *6) were still significantly 
lower (less than one-half of the endoxifen concentrations 
for EMs) despite receiving a double dose (40 mg) of TAM 
[10]. A genotype-guided intra-patient dose-escalation study 
of TAM conducted in Japan also suggested that patients 
homozygous for CYP2D6*10 may achieve lower concen-
trations of endoxifen despite receiving 40 mg of TAM [6]. 
Table 1  Background of the 273 patients in the screening study
Mean SD Median Min Max
Age (years) 52.5 10.7 50.0 27.0 84.0
Weight (kg) 53.5 8.4 52.9 30.0 90.0
Height (cm) 156.6 5.7 156.5 140.0 173.0
BSA  (m2) 1.52 0.12 1.51 1.11 1.94
Anti-estrogen/dose
 TAM/20 mg 182 66.7%
 TOR/40 mg 61 22.3%
 TOR/120 mg 30 11.0%
Hot flush grade
 0 164 60.1% 273
 1 81 29.7%
 2 27 9.9%
 3 1 0.4%
Hot flush grade
 0 105 56.8%
TAM 20 mg
 1 58 31.4%
 2 21 11.4%
 3 1 0.5%
Hot flush grade
 0 35 57.4%
TOR 40 mg
 1 20 32.8%
 2 6 9.8%
 3 0 0.0%
Hot flush grade
 0 24 88.9%
TOR 120 mg
 1 3 11.1%
 2 0 0.0%
 3 0 0.0%
Smoking
 Yes 15 5.5%
 No 254 93.0%
 Unknown 4 1.5%
CYP inhibitor use
 2D6 3 1.1%
 3A4 12 4.4%
 Both 14 5.1%
 None 244 89.4%
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Because the contribution of CYP2D6 to TOR metabolism is 
relatively small, TOR might be a valid alternative to TAM, 
especially in patients predicted to be PMs of TAM. Further 
clinical trials are warranted to validate this concept.
Although the concentrations of the 4OH metabolites of 
TAM, such as endoxifen, in relation to the CYP2D6 geno-
type and TAM dose have been measured in clinical studies 
in both Western and Asian populations [6, 10], the active 
metabolites of TOR have not been determined in clinical 
trial samples. The results of a recent in vitro study suggested 
that the contribution of CYP2D6 to the bioactivation of TOR 
is lower than that of TAM [11].
In conclusion, genotyping for CYP2D6 is not enough 
to predict endoxifen or the total activity of TAM, because 
there are large overlaps between different genotype groups; 
therefore, a strategy incorporating therapeutic drug moni-
toring may be more logical, especially in populations with 
higher proportions of PMs, such as Asian populations. Fur-
thermore, for patients found to be PMs of TAM, TOR may 
be a good candidate; however, this approach needs to be 
validated in prospective clinical trials using efficacy as an 
endpoint.
Fig. 2  Distribution of endoxifen (a) and total activity (b) of patients in the screening study (SC)
Table 2  Background of the 14 patients in the intra-patient dose-esca-
lation clinical pharmacology study for TOR
Mean SD Median Min Max
Age (years) 50.1 7.9 47.0 43.0 68.0
Height (cm) 159.7 5.1 159.8 151.0 167.0
Performance status
 0 14 100.0%
 1–2 0.0 0.0%
Endoxifen on 
TAM 20 mg
9.7 3.1 10.4 1.8 12.6
CYP2D6 phenotype
 1 (null/null) 0 0.0%
 2 (null/wt) 0 0.0%
 3 (low/low) 7 50.0%
 4 (null/low) 5 35.7%
 5 (low/wt) 2 14.3%
 6 (wt/wt) 0 0.0%
Hot flush grade on TAM 20 mg
 0 8 57.1%
 1 4 28.6%
 2 2 14.3%
CYP inhibitor use
 2D6 0 0.0%
 3A4 1 7.1%
 Both 1 7.1%
 None 12 85.7%
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Table 3  Associations between 
the total activity of TAM or 
TOR and gene polymorphisms
Total activity of TAM (N = 159) Total activity of TOR (N = 77)
Mean 95% CI p Mean 95% CI p
Intercept 2063.3 1468.9 2657.7 – 10315.0 7924.2 12706.0 –
Dose of TOR
 40 mg – – – – −4903.1 −6052.7 −3753.4 < 0.01
 120 mg – – – – Ref – – –
CYP2C19 phenotype
 EM −79.7 −441.6 282.3 0.90 979.6 −584.3 2543.5 0.07
 Hetero −75.9 −413.1 261.4 – −171.9 −1679.6 1335.7 –
 PM Ref – – – Ref – – –
CYP2D6 phenotype
 1 (null/null) −1569.1 −2874.5 −263.6 < 0.01 No patient – – 0.61
 2 (null/wt) −768.0 −1269.3 −266.6 – −593.5 −2523.4 1336.5 –
 3 (low/low) −1034.8 −1358.7 −710.9 – −685.9 −2067.5 695.7 –
 4 (null/low) −1232.2 −1661.4 −803.1 – −713.2 −3644.0 2217.5 –
 5 (low/wt) −442.7 −682.9 −202.4 – 303.4 −773.8 1380.7 –
 6 (wt/wt) Ref – – – Ref – – –
ABCC2 genotype
 mut/mut 102.9 −214.2 420.0 0.33 716.8 −583.2 2016.9 0.46
 mut/wt 171.0 −53.8 395.7 – 581.8 −480.6 1644.1
 wt/wt Ref – – – Ref – – –
Current smoking status 275.1 −199.3 749.4 0.25 −2265.1 −4743.8 213.6 0.07
Concurrent strong 3A4 
or 2D6 inhibitor use
−786.5 −2089.5 516.4 0.23 1187.1 −2733.5 5107.8 0.55
Fig. 3  Distribution of the total activity of patients in the screening 
study (SC) and the intra-patient dose-escalation clinical pharmacol-
ogy study for TOR (CP 1st and 2nd) (a) and individual patients’ lev-
els during dose escalation and maintenance in the intra-patients dose-
escalation clinical pharmacology study for TOR (b)
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